Kedrion completes its portfolio of hemophilia products
The company will distribute in Italy the first recombinant factor VIII from human cell line
Investigating inhibitor development in patients with Hemophilia A
Lecture on state-of-the-art of the SIPPET Study presented by P.M. Mannucci, sponsored by Grifols, Kedrion and LFB
Kedrions’ immunoglobulin approved for the treatment of CIDP in Italy
The ruling published by AIFA in the Official Journal, on 23rd June 2014
EmoKed, software for traceability, transparency and efficiency
The new online platform developed by Kedrion provides strategic support to the Italian Transfusion System
Kedrion collection centers first to be certified in Hungary
Plazmaferezis Állomás Kft achieves international PPTA certification
Distribution of the first recombinant Factor VIII from human cells
Kedrion to be the distributor in Italy over the next ten years. The indication is the treatment of…
Kedrion presents the new Factor VIII for the Hungarian market
Today, at the Hungarian Academy of Sciences in Budapest, a scientific symposium celebrated the launch on the Hungarian market of the new plasma-derived product Factor VIII by Human BioPlazma, Kedrion Group’s Budapest-based subsidiary, which runs the production plant of Gödöllő. Manufactured at the production plant of Bolognana through the purification of an intermediate product received
Agreement with Entegrion for the development and marketing of Resusix™, a virus inactivated spray-dried plasma
Kedrion Melville Inc., a US-based company owned by Kedrion, entered into an agreement with the US-based company Entegrion Inc. for the development and marketing of Resusix™, a virus inactivated spray-dried plasma, treated with solvent-detergent, to be used as a replacement of frozen fresh plasma. The Phase-I clinical trials that have recently been authorised by the
Kedrion, sole supporter of the website of the Italian Society for the study of the Perupheral Nervous System
Kedrion continues and upgrades its policy in support of the Italian Society for the Study of the Peripheral Nervous System. Actually, the company is the sole supporter of the Society’s website www.asnp.net , with the homepage hosting Kedrion’s logo as a direct link to our website. The Italian Society for the Study of the Peripheral
Rare diseases: Kedrion hoping for temporary authorisation for use of drugs (ATU) in Italy
«It is essential to insist on how important the ATU, i.e. Autorizzazione Temporanea di Utilizzo or Temporary Authorisation for use of orphan or life saving drugs, is for patients, so that quick access is given to such class of drugs while guaranteeing the products’ safety». This was stated by Rodolfo de Dominicis, Deputy President of